Bortezomib.
Paramore
Andrew
A
Decision Resources International, London, UK. aparamore@decisionresources.co.uk
Frantz
Simon
S
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D001897:Boronic Acids / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D011719:Pyrazines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib